Global Blood Therapeutics, Inc. (NASDAQ:GBT) has earned a consensus rating of “Buy” from the fifteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $55.70.

A number of equities analysts have recently weighed in on the company. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th. Morgan Stanley reaffirmed an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $46.00 price target (up from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. Needham & Company LLC started coverage on Global Blood Therapeutics in a report on Wednesday, September 20th. They set a “buy” rating and a $51.00 price target on the stock. Finally, Wedbush reiterated an “ourperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a report on Monday, September 18th.

TRADEMARK VIOLATION NOTICE: “Global Blood Therapeutics, Inc. (GBT) Given Average Recommendation of “Buy” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/04/global-blood-therapeutics-inc-gbt-given-average-recommendation-of-buy-by-analysts.html.

In related news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now owns 143,255 shares of the company’s stock, valued at approximately $4,297,650. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the sale, the director now directly owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,053 shares of company stock worth $1,073,204. 5.30% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Asset Management One Co. Ltd. purchased a new stake in Global Blood Therapeutics during the first quarter valued at about $130,000. Great West Life Assurance Co. Can bought a new position in Global Blood Therapeutics during the first quarter worth about $129,000. BNP Paribas Arbitrage SA increased its stake in shares of Global Blood Therapeutics by 694.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after purchasing an additional 3,975 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Global Blood Therapeutics by 10.1% in the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after purchasing an additional 440 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of Global Blood Therapeutics in the first quarter worth about $230,000. 86.07% of the stock is currently owned by institutional investors and hedge funds.

Global Blood Therapeutics (GBT) traded up 8.92% on Wednesday, hitting $32.35. The company had a trading volume of 2,250,749 shares. The stock has a 50 day moving average of $28.26 and a 200-day moving average of $29.61. Global Blood Therapeutics has a one year low of $13.35 and a one year high of $41.15. The stock’s market capitalization is $1.41 billion.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same quarter in the previous year, the business posted ($0.58) earnings per share. Equities analysts anticipate that Global Blood Therapeutics will post ($2.44) EPS for the current year.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.